Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

13 results
Display

Valsartan Dosage on Ventriculo-Vascular Coupling Index Dose-Dependency in Heart Failure Patients

Ahn KJ, Yu J, Jang AY, Kim DH, Kwan J, Chung WJ

Purpose: Heart failure (HF) poses significant morbidity and mortality. Recently, the ventriculo-vascular coupling index (VVI) was introduced as an independent prognostic factor reflective of the overall cardiovascular performance index in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Addition of Amlodipine or Valsartan for Improvement of Diastolic Dysfunction Associated with Hypertension

Oh JK, Seo JS, Park YH, Park JH, Lee SA, Lee S, Kim DH, Song JM, Kang DH

BACKGROUND: Hypertensive patients are at increased risk of diastolic dysfunction. The hypothesis of this study was that addition of amlodipine would be superior to valsartan in improving diastolic dysfunction associated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril–valsartan in Heart Failure with Reduced Ejection Fraction

Kim BJ, Park HS, Im SI, Kim HS, Heo JH, Cha TJ, Cho KI

BACKGROUND: Recent studies have demonstrated that angiotensin receptor neprilysin inhibitors (ARNIs) can reverse the cardiac remodeling effects that occur in heart failure with reduced ejection fraction (HFrEF). These studies have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction

Dewan P, Docherty K, McMurray J

The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Issues on carcinogen contaminated antihypertensive drugs and constructing drug safety management system

Park BJ

European Medicines Agency withdrew valsartan from European market in July 2018 because it was contaminated with carcinogen, N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA). Medicines and Healthcare Products Regulatory Agency also found...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Eligibility for Sacubitril/ Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry

Oh J, Lee CJ, Park JJ, Lee SE, Kim MS, Cho HJ, Choi JO, Lee HY, Hwang KK, Kim KH, Yoo BS, Choi DJ, Baek SH, Jeon ES, Kim JJ, Cho MC, Chae SC, Oh BH, Kang SM

Background and Objectives: Sacubitril/valsartan (SV, LCZ696), the first in class drug, called as angiotensin receptor-neprilysin inhibitor (ARNI) can reduce heart failure (HF) hospitalization and cardiovascular mortality. However, SV prescription rate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study

Kim HJ, Han SJ, Kim DJ, Jang HC, Lim S, Choi SH, Kim YH, Shin DH, Kim SH, Kim TH, Ahn YB, Ko SH, Kim NH, Seo JA, Kim HY, Lee KW

BACKGROUND/AIMS: Oxidative stress plays an important role in the pathogenesis and progression of diabetic complications and antagonists of renin-angiotensin system and amlodipine have been reported previously to reduce oxidative stress....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Valsartan 160 mg/Amlodipine 5 mg Combination Therapy versus Amlodipine 10 mg in Hypertensive Patients with Inadequate Response to Amlodipine 5 mg Monotherapy

Sung J, Jeong JO, Kwon SU, Won KH, Kim BJ, Cho BR, Kim MK, Lee S, Kim HJ, Lim SH, Park SW, Park JE

BACKGROUND AND OBJECTIVES: When monotherapy is inadequate for blood pressure control, the next step is either to continue monotherapy in increased doses or to add another antihypertensive agent. However, direct...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients

Jang JY, Lee SH, Kim BS, Seo HS, Kim WS, Ahn Y, Lee NH, Koh KK, Kang TS, Jo SH, Hong BK, Bae JH, Yang HM, Cha KS, Kim BS, Kwak CH, Cho DK, Kim U, Zo JH, Kang DH, Pyun WB, Chun KJ, Namgung J, Cha TJ, Juhn JH, Jung Y, Jang Y

BACKGROUND AND OBJECTIVES: We compared the efficacy and safety of valsartan and rosuvastatin combination therapy with each treatment alone in hypercholesterolemic hypertensive patients. SUBJECTS AND METHODS: Patients who met inclusion criteria...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacokinetic and Pharmacodynamic Study Determines Factors Affecting Blood Pressure Response to Valsartan

Cho JM, Yim SV, Jin H, Sohn IS, Hwang HJ, Park CB, Jin ES, Kim CJ

  • KMID: 2330957
  • J Korean Soc Hypertens.
  • 2012 Sep;18(3):88-96.
BACKGROUND: Valsartan is an angiotensin II receptor blocker and is used for patient with hypertension. Although response to valsartan varies each individual, there is no study about factors affecting the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Telmisartan Versus Valsartan in Patients With Hypertension: Effects on Cardiovascular, Metabolic, and Inflammatory Parameters

Lim SY, Kim SW, Kim EJ, Kang JH, Kim SA, Kim YK, Na JO, Choi CU, Lim HE, Han SW, Rha SW, Park CG, Seo HS, Oh DJ

BACKGROUND AND OBJECTIVES: Angiotensin-receptor blockers (ARBs) have beneficial effects on cardiovascular, metabolic, and inflammatory parameters in addition to controlling blood pressure (BP). However, few comparative clinical studies have been conducted...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effects of Telmisartan Compared with Valsartan on Plasma Adiponectin Levels and Arterial Stiffness in Patients with Type 2 Diabetes: A Pilot Study

Park SY, Kim SG, Park J, Lee YJ, Kim HY, Seo JA, Kim NH, Choi KM, Baik SH, Choi DS

BACKGROUND: Telmisartan, used for the treatment of hypertension, has been shown to function as a partial agonist of peroxime proliferative activated receptor-nu (PPAR-nu). Theoretically, telmisartan which simultaneously blocks the angiotensin...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Effect of Valsartan on Blood Pressure and Urinary Albumin Excretion in Hypertensive Type 2 Diabetic Patients: An Open-Label, Multicenter Study

Park SJ, Kim DJ, Kim HJ, Park SY, Seo JA, Kim NH, Choi SH, Lim S, Jang HC, Ko SH, Song KH, Ahn YB, Kim SK, Cho YW, Kang JG, Ihm SH, Park CY, Park SW, Shin DH, Kim YH, Lee KW

BACKGROUND: Activation of renin-angiotensin system (RAS) has been an important mechanism of microvascular and macrovascular complications in diabetic patients. It has been reported that RAS blockades reduce the development and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr